Denver, Colo. - Neuroendocrine cancer is exceedingly difficult to manage and unlikely to be cured, but researchers intend to slow progression of these tumors and aid survival by personalizing patient ...
Peptide receptor radionuclide therapy (PRRT) with lutetium dotatate is a treatment for well-differentiated neuroendocrine tumors that the U.S. Food and Drug Administration approved in 2018, but ...
For 177Lu-PRRT, the mean number of cycles administered was 5.3 ± 2.5; for 90Y-PRRT, the mean number of cycles administered was 5.5 ± 2.6. Median overall survival was 79 months, but 32 percent of the ...
A phase II study of bevacizumab (BEV) plus erlotinib (ERL) in patients with gemcitabine (GEM)-refractory metastatic pancreatic cancer (MPC) No significant financial relationships to disclose. This is ...
PRRT can also be effective for patients with nongastroenteropancreatic tumors, such as non-radioiodine-avid thyroid carcinoma and paraganglioma; however, further studies are needed to determine PRRT's ...
"So far, the majority of PRRT treatments have been administered one-size-fits-all, meaning every patient receives about the same amount of radioactivity," said Jean-Mathieu Beauregard, MD, assistant ...
Neuroendocrine cancer can be exceedingly difficult to manage and can be unlikely to be cured. A research team from the Society of Nuclear Medicine has intended to slow down the progression of these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results